Literature DB >> 14705110

Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions.

Inge Huitinga1, Zeynel A Erkut, Denis van Beurden, Dick F Swaab.   

Abstract

In this postmortem study, we investigated the relationship between multiple sclerosis (MS) lesions in the hypothalamus and the state of activity of corticotropin-releasing hormone (CRH)-producing neurons that control the hypothalamus-pituitary-adrenal (HPA) axis. A high incidence (15/16) of MS lesions was found in the hypothalamus, of which more than 50% was active, that is, contained activated macrophages. MS patients have increased numbers of CRH-immunoreactive neurons coexpressing vasopressin (CRH/VP neurons), a sign of chronic activation of CRH neurons and increased CRH mRNA expression. Active MS lesions correlated with a low number of hyperactive CRH/VP neurons. High human leukocyte antigen (HLA)-DR, -DP, -DQ expression, a measure for macrophage and microglial activation, correlated with low CRH mRNA expression. The nearer the HLA expression was situated to the CRH neurons, the stronger the inhibiting effect, suggesting that activated microglial cells or macrophages suppress these neurons. The more active MS lesions were present in the hypothalamus, the shorter was the disease duration until the moment of death, indicating an unfavorable course of the disease. Thus, MS patients have a chronically activated CRH system, but, in the subgroup of patients with active MS lesions in the hypothalamus, this activation is impaired and the disease course is worse.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14705110     DOI: 10.1002/ana.10766

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  20 in total

Review 1.  Multiple sclerosis and sexual dysfunction.

Authors:  Zhen-Ni Guo; Si-Yuan He; Hong-Liang Zhang; Jiang Wu; Yi Yang
Journal:  Asian J Androl       Date:  2012-03-26       Impact factor: 3.285

2.  Prolactin is Not Associated with Disability and Clinical Forms in Patients with Multiple Sclerosis.

Authors:  Wildéa Lice de Carvalho Jennings Pereira; Tamires Flauzino; Daniela Frizon Alfieri; Sayonara Rangel Oliveira; Ana Paula Kallaur; Andrea Name Colado Simão; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Neuromolecular Med       Date:  2019-08-31       Impact factor: 3.843

Review 3.  Autonomic dysfunction in multiple sclerosis: implications for exercise.

Authors:  Mu Huang; Ollie Jay; Scott L Davis
Journal:  Auton Neurosci       Date:  2014-10-23       Impact factor: 3.145

4.  Hair cortisol concentration, cognitive, behavioral, and motor impairment in multiple sclerosis.

Authors:  Gabriela Magalhães Pereira; Jefferson Becker; Nayron Medeiros Soares; Lucas Araújo de Azeredo; Rodrigo Grassi-Oliveira; Andreo Rysdyk; Rosa Maria Martins de Almeida
Journal:  J Neural Transm (Vienna)       Date:  2019-06-27       Impact factor: 3.575

Review 5.  Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment.

Authors:  Claudio Solaro; Giulia Gamberini; Fabio Giuseppe Masuccio
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 6.  Gray matter imaging in multiple sclerosis: what have we learned?

Authors:  Hanneke E Hulst; Jeroen J G Geurts
Journal:  BMC Neurol       Date:  2011-12-12       Impact factor: 2.474

Review 7.  Targeting the gut to treat multiple sclerosis.

Authors:  Laura Ghezzi; Claudia Cantoni; Gabriela V Pinget; Yanjiao Zhou; Laura Piccio
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

8.  A Negative Association of Hypothalamic Volume and Perceived Stress in Patients with Atopic Dermatitis.

Authors:  Hideki Mochizuki; Christina Schut; Alina Shevchenko; Rodrigo Valdes-Rodriguez; Leigh A Nattkemper; Gil Yosipovitch
Journal:  Acta Derm Venereol       Date:  2020-05-11       Impact factor: 3.875

9.  Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis.

Authors:  L K Fisniku; D R Altmann; M Cercignani; D J Tozer; D T Chard; J S Jackson; K A Miszkiel; K Schmierer; A J Thompson; D H Miller
Journal:  Mult Scler       Date:  2009-05-12       Impact factor: 6.312

10.  Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone.

Authors:  Amy Perrin Ross; Aliza Ben-Zacharia; Colleen Harris; Jennifer Smrtka
Journal:  Front Neurol       Date:  2013-03-08       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.